Mizuho Securities analyst Salim Syed maintained a Buy rating on Amgen Inc (AMGN) on June 14 and set a price target of $208. The company’s shares closed yesterday at $181.61.
According to TipRanks.com, Syed is a 1-star analyst with an average return of -3.3% and a 45.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Neon Therapeutics Inc.
Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $208.92, a 15.0% upside from current levels. In a report issued on June 3, Cowen & Co. also assigned a Buy rating to the stock with a $229 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $210.19 and a one-year low of $166.30. Currently, Amgen Inc has an average volume of 2.83M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
